Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study
Author:
Affiliation:
1. Department of Endocrinology Qianan Yanshan Hospital Hebei China
2. Department of Endocrinology Qinhuangdao Hospital of Traditional Chinese Medicine Qinhuangdao Hebei China
3. North China University of Science and Technology Tangshan Hebei China
Funder
Natural Science Foundation of Hebei Province
Publisher
Wiley
Subject
Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/osp4.342
Reference31 articles.
1. Growing Trend of China's Contribution to Global Diabetes Research
2. The Diabetes Epidemic in China: An Integrated Review of National Surveys
3. The uneven seepage of science: Diabetes and biosociality in China
4. Prevalence and Control of Diabetes in Chinese Adults
5. Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database;Pharmaceuticals;2024-01-23
2. Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial;Frontiers in Endocrinology;2023-12-06
3. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study;Diabetes, Obesity and Metabolism;2023-11-09
4. The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial;Journal of Diabetes;2023-10-20
5. A narrative review of approved and emerging anti-obesity medications;Saudi Pharmaceutical Journal;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3